Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Leila Jahromi

Physician Assistant Washington, DC Physician Assistant

NPI 1063158715 CMS profile 11413428

3800 Reservoir Rd Nw, Transplant Department 2Phc, Washington, DC 20007

Open in the dashboard

General payments

$863

53 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leila Jahromi of Washington, DC is reported in the CMS Open Payments database as having received $863 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $118 4
2024 General $27 1
2023 General $589 41
2022 General $128 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leila Jahromi
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Leila Jahromi were reported at $118. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Leila Jahromi Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $128 $155 $48–$522 $149
2023 $589 $167 $52–$557 $160
2024 $27 $178 $55–$600 $164
2025 $118 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novartis Pharmaceuticals Corporation $181 20 payments
  2. Lilly USA, LLC $122 6 payments
  3. Inspire Medical Systems, Inc. $111 4 payments
  4. Teva Pharmaceuticals USA, Inc. $76 4 payments
  5. Argenx US, Inc. $66 3 payments
  6. Pfizer Inc. $55 3 payments
  7. Lundbeck LLC $42 2 payments
  8. AbbVie, Inc. $36 2 payments
  9. Aerin Medical Inc. $34 1 payment
  10. Impel Pharmaceuticals Inc. $30 2 payments
  11. Other $109 6 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $806 51 payments
  2. Travel and Lodging $57 2 payments
Products named General payments · program years 2022–2025
  1. KESIMPTA $181 20 payments
  2. MAYZENT $181 20 payments
  3. EMGALITY $122 6 payments
  4. REYVOW $122 6 payments
  5. INSPIRE $111 4 payments
  6. AUSTEDO $76 4 payments
  7. VYVGART $66 3 payments
  8. NURTEC ODT $55 3 payments
  9. VYEPTI $42 2 payments
  10. VIVAER STYLUS $34 1 payment
  11. Other $268 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$2,433

Medicare's payments for the services billed

Medicare patients

34

Average age 69

Services billed

34

15 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 38%
Depression 35%
Arthritis 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record